SCHEMBL5134976

SCHEMBL5134976

CCCCn1c(-c2ccccc2)nc(-c2ccccc2)c1CN(Cc1c(F)cccc1Cl)CC1CCCCC1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
C5AR1 P21730 1/20 0.37
TSHR P16473 4/20 0.35
KDM4E B2RXH2 3/20 0.35
ALDH1A1 P00352 3/20 0.35
CYP3A4 P08684 3/20 0.35
HSD17B10 Q99714 3/20 0.35
HPGD P15428 2/20 0.35
CRHR1 P34998 3/20 0.34
ALOX15 P16050 2/20 0.33
ADORA3 P0DMS8 2/20 0.33
ADORA2A P29274 2/20 0.33
ADORA2B P29275 2/20 0.33
ADORA1 P30542 2/20 0.33
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
PDE6D O43924 1/20 0.33
CCR4 P51679 1/20 0.33
HDAC1 Q13547 1/20 0.32
CASP1 P29466 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5135466 0.94 C5AR1 (0.39) C5AR1TSHRKDM4EALDH1A1CYP3A4
SCHEMBL5135032 0.94 C5AR1 (0.39) C5AR1TSHRKDM4EALDH1A1CYP3A4
SCHEMBL5136106 0.87 C5AR1 (0.41) C5AR1TSHRKDM4EALDH1A1CYP3A4
SCHEMBL5135152 0.87 C5AR1 (0.41) C5AR1TSHRKDM4EALDH1A1CYP3A4
SCHEMBL5137537 0.87 C5AR1 (0.34) C5AR1TSHRKDM4EALDH1A1CYP3A4
SCHEMBL5135866 0.87 C5AR1 (0.39) C5AR1TSHRKDM4EALDH1A1CYP3A4
SCHEMBL650740 0.87 C5AR1 (0.39) C5AR1TSHRKDM4EALDH1A1CYP3A4
SCHEMBL650928 0.86 C5AR1 (0.43) C5AR1TSHRKDM4EALDH1A1CYP3A4
SCHEMBL649094 0.86 C5AR1 (0.43) C5AR1TSHRKDM4EALDH1A1CYP3A4
SCHEMBL5134752 0.86 C5AR1 (0.39) C5AR1TSHRKDM4EALDH1A1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed